CANY
AQST icon

Caxton Associates (New York)’s Aquestive Therapeutics AQST Stock Holding History

Caxton Associates (New York)’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42,028
Closed -$163K – 511
2021
Q4 		$163K Buy
+42,028
New +$211K 0.02% 505

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

Caxton Associates (New York)'s AQST Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Aquestive Therapeutics (AQST) in Q1 2022, closing a stake of 42,028 shares — an estimated $163K sold.

Caxton Associates (New York) first reported a position in AQST in Q4 2021 and held it in 1 quarter. The position peaked at $163K in Q4 2021. 51 funds tracked by Wall St. Rank hold AQST as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Aquestive Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 42,028 Aquestive Therapeutics shares in Q1 2022, an estimated $163K.
  • Caxton Associates (New York) first reported a position in Aquestive Therapeutics in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Aquestive Therapeutics position peaked at $163K in Q4 2021.
  • 51 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.